Dataset Information

Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect.

ABSTRACT: The pyrazolone structural motif is a critical element of drugs aimed at different biological end-points. Medicinal chemistry researches have synthesized drug-like pyrazolone candidates with several medicinal features including antimicrobial, antitumor, CNS (central nervous system) effect, anti-inflammatory activities and so on. Meanwhile, SAR (Structure-Activity Relationship) investigations have drawn attentions among medicinal chemists, along with a plenty of analogues have been derived for multiple targets. In this review, we comprehensively summarize the biological activity and SAR for pyrazolone analogues, wishing to give an overall retrospect and prospect on the pyrazolone derivatives.

SUBMITTER: Zhao Z

PROVIDER: S-EPMC7115706 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect.

Zhao Zefeng Z Dai Xufen X Li Chenyang C Wang Xiao X Tian Jiale J Feng Ying Y Xie Jing J Ma Cong C Nie Zhuang Z Fan Peinan P Qian Mingcheng M He Xirui X Wu Shaoping S Zhang Yongmin Y Zheng Xiaohui X

European journal of medicinal chemistry 20191116

The pyrazolone structural motif is a critical element of drugs aimed at different biological end-points. Medicinal chemistry researches have synthesized drug-like pyrazolone candidates with several medicinal features including antimicrobial, antitumor, CNS (central nervous system) effect, anti-inflammatory activities and so on. Meanwhile, SAR (Structure-Activity Relationship) investigations have drawn attentions among medicinal chemists, along with a plenty of analogues have been derived for mul ...[more]

PMID: 31761383

Similar Datasets

Project description:The Gorumara National Park (GNP) is an important conservation area located in the northern region of West Bengal State, India, as it provides habitat for three megaherbivores: Indian One-horned rhinoceros (Rhinoceros unicornis), Asian elephants (Elephas maximus) and Gaurs (Bos gaurus). It harbours one of the last population of the one-horned rhino. In the present study, landscape change and configuration were investigated by comparing three Landsat images, from 1998, 2008 and 2018. The images were classified into six different landcover classes following standard methodology. The present study also involves evaluation of landscape and anthropogenic predictors influence on the megaherbivores of GNP, followed by future landcover simulation for the year 2028. The result shows a significant decrease in the grassland cover from 18.87 km2 to 8.27 km2 from 1998 to 2018, whereas the woodland cover has increased from 50.14 km2 to 62.09 km2 between 1998 and 2018. The landscape configuration indices such as Number of Patches (NP), Patch Density (PD), Interspersion and Juxtaposition (IJI), Aggregation Index (AI) and Mean Shape Index (SHAPE AM) indicated that the landscapes has lost complexity in the spatial placement of patches of different Land Use and Land Cover (LULC) classes. Also, the landscape over the three decades has become uniform in terms of diversity of patches, because of earlier plantation activities by the forest managers. Result also indicated that grassland, along with its class metrics are the top predictors contributing 43.6% in explaining the spatial distribution of megaherbivores in GNP. Results from the simulated landcover of 2028 suggest a possible decline in overall grassland by 6.23% and a subsequent upsurge in woodland by 6.09% from 2018. The present result will be useful in guiding the forest management in developing habitat improvement strategies for the long- term viability of megaherbivore populations of rhino, gaur and elephant in the GNP.

Project description:Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer-related deaths in China. The recent emergence of immunotherapy treatment options, such as the use of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors, has also led to a paradigm shift in the treatment of non-small cell lung cancer, and has provided promising directions for the treatment of small cell lung cancer. This review provides a summary of the developmental process of immunotherapy, especially immune checkpoint inhibitors in lung cancer, ongoing international and domestic clinical trials in this field, and the challenges and considerations related to the use of immunotherapy in Chinese patients with lung cancer, with the aim of providing detailed information for future immunotherapy-related clinical trials in China. Research regarding immune checkpoint inhibitors in China is several years behind similar research in several developed countries. However, although PD-1/PD-L1 inhibitor-related clinical trials remain in their early stages in China, increased efforts by Chinese clinicians, researchers, and government staff have been directed toward trying to introduce novel drugs into the clinical setting. Because of the specific characteristics of Chinese patients with lung cancer (such as high epidermal growth factor receptor mutation rates, later disease stages, and different toxicity profiles), large-scale clinical trials targeting the Chinese population or Chinese participation in multinational trials should be promoted. IMPLICATIONS FOR PRACTICE: As the leading cause of cancer-related morbidity and mortality, lung cancer is a major public health problem in China. Immunotherapy based on programmed cell death protein 1/programmed death-ligand 1 checkpoint inhibitors may result in new treatment directions and a paradigm shift for Chinese patients with lung cancer. Although checkpoint inhibitor-related clinical trials remain in their early stages in China, increased efforts by Chinese clinicians, researchers, and government staff have been directed toward trying to introduce novel drugs into the clinical setting by encouraging the development of large-scale clinical trials targeting the Chinese population and promoting Chinese patients with lung cancer to participate in international trials.

Dataset Information

Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect.

Publications

Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets